Clinical accuracy of a PLEX-ID flu device for simultaneous detection and identification of influenza viruses A and B Journal Article


Authors: Tang, Y. W.; Lowery, K. S.; Valsamakis, A.; Schaefer, V. C.; Chappell, J. D.; White-Abell, J.; Quinn, C. D.; Li, H.; Washington, C. A.; Cromwell, J.; Giamanco, C. M.; Forman, M.; Holden, J.; Rothman, R. E.; Parker, M. L.; Ortenberg, E. V.; Zhang, L.; Lin, Y. L.; Gaydos, C. A.
Article Title: Clinical accuracy of a PLEX-ID flu device for simultaneous detection and identification of influenza viruses A and B
Abstract: Respiratory tract infections caused by influenza A and B viruses often present nonspecifically, and a rapid, high-throughput laboratory technique that can identify influenza viruses is clinically and epidemiologically desirable. The PLEX-ID Flu assay (Abbott Molecular Inc., Des Plaines, IL) incorporates multilocus PCR and electrospray ionization-mass spectrometry to detect and differentiate influenza A 2009 H1N1 (H1N1-p), seasonal H1N1 (H1N1-s), influenza A H3N2, and influenza B viruses in nasopharyngeal swab (NPS) specimens. The clinical performance characteristics of the PLEX-ID Flu assay in symptomatic patients were determined in this multicenter trial. A total of 2,617 prospectively and retrospectively collected NPS specimens from patients with influenza-like illness between February 2008 and 28 May 2010 were eligible for inclusion in the study. Each specimen was tested in parallel by the PLEX-ID Flu assay and by the Prodesse ProFLU+ assay (Prodesse Inc., Madison, WI), to detect influenza A and B viruses. Specimens testing positive for influenza A virus by ProFLU+ were subtyped as H1N1-p, H1N1-s, or H3N2 by using the ProFAST+ assay (Gen-Probe Prodesse Inc.). The reproducibility of the PLEX-ID Flu assay ranged from 98.3 to 100.0%, as determined by testing a nine-specimen panel at three clinical sites on each of 5 days. Positive percent agreements (PPAs) and negative percent agreements (NPAs) of the PLEX-ID Flu assay were 94.5% and 99.0% for influenza A virus and 96.0% and 99.9% for influenza B virus, respectively. For the influenza A virus subtyping characterization, the PLEX-ID Flu assay had PPAs and NPAs of 98.3% and 97.5% for H1N1-p, 88.6% and 100.0% for H1N1-s, and 98.0% and 99.9% for H3N2, respectively. The overall agreements between the PLEX-ID and Prodesse ProFLU+/ProFAST+ assays were 97.1 to 100.0%. Bidirectional Sanger sequencing analysis revealed that 87.5% of 96 discrepant results between the PLEX-ID Flu and ProFLU+/ProFAST+ assays were found upon influenza A virus detection and H1N1-p subtyping. The PLEX-ID Flu assay demonstrated a high level of accuracy for the simultaneous detection and identification of influenza A and B viruses in patient specimens, providing a new laboratory tool for the rapid diagnosis and management of influenza A and B virus infections. Copyright © 2013, American Society for Microbiology. All Rights Reserved.
Keywords: controlled study; gene sequence; major clinical study; sequence analysis; nonhuman; diagnostic accuracy; polymerase chain reaction; reproducibility; multicenter study; nucleotide sequence; intermethod comparison; flu like syndrome; influenza virus a; influenza virus b; virus identification; influenza virus a h1n1; virus gene; diagnostic test accuracy study; electrospray mass spectrometry; nose smear; laboratory device; influenza virus a h3n2; throat culture
Journal Title: Journal of Clinical Microbiology
Volume: 51
Issue: 1
ISSN: 0095-1137
Publisher: American Society for Microbiology  
Date Published: 2013-01-01
Start Page: 40
End Page: 45
Language: English
DOI: 10.1128/jcm.01978-12
PROVIDER: scopus
PUBMED: 23077123
PMCID: PMC3536229
DOI/URL:
Notes: --- - "Export Date: 1 February 2013" - "CODEN: JCMID" - "Molecular Sequence Numbers: GENBANK: HM189312, JQ714075;" - "Source: Scopus"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Yi-Wei Tang
    188 Tang